Wyeth Will Lose 18.5% Of Marietta Sales If Firm Does Not Comply With GMPs
Executive Summary
Wyeth-Ayerst would have to pay the government 18.5% of future net sales from products manufactured at its Marietta, Penn. facility if it fails to meet a timeline for bringing the plant into compliance with current Good Manufacturing Practices under an Oct. 3 consent decree with FDA.
You may also be interested in...
Wyeth Packaging Problems Lead To Warning Letter, Triphasil-28 Recall
Wyeth failed to adequately investigate cases of contamination involving a packaging extractable for two oral contraceptive drugs manufactured at the firm's Guayama, Puerto Rico facility, FDA states in a recent warning letter
Wyeth Packaging Problems Lead To Warning Letter, Triphasil-28 Recall
Wyeth failed to adequately investigate cases of contamination involving a packaging extractable for two oral contraceptive drugs manufactured at the firm's Guayama, Puerto Rico facility, FDA states in a recent warning letter
Fluarix Clears FDA; GSK Buys Vaccine Manufacturing Plant From Wyeth
GlaxoSmithKline is expanding its vaccine manufacturing capability as it prepares for its flu vaccine Fluarix to enter the U.S. market and in anticipation of several vaccine approvals over the next few years